Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Nucleic Acids Research|April 30, 2021
Short DNA/RNA heteroduplex oligonucleotide interacting proteins are key regulators of target gene silencingKen Asada, Fumika Sakaue, Tetsuya Nagata, et al.
Journal of Pain Research|November 27, 2020
DNA Microarray Analysis of Differential Gene Expression in the Dorsal Root Ganglia of Four Different Neuropathic Pain Mouse ModelsHiroyuki Yokoyama, Takashi Hirai, Tetsuya Nagata, et al.
Molecular Therapy. Nucleic Acids|February 4, 2015
Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 miceYusuke Echigoya, Yoshitsugu Aoki, Bailey Miskew, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 8, 2021
Structural tuning of oligonucleotides for enhanced blood circulation properties of unit polyion complexes prepared from two-branched poly(ethylene glycol)-block-poly(l-lysine)Mitsuru Naito, Hiroyuki Chaya, Kazuko Toh, et al.
Nucleic Acid Therapeutics|August 15, 2012
Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogsToshifumi Yokota, Akinori Nakamura, Tetsuya Nagata, et al.
Nature Communications|December 23, 2021
DNA/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivoMasaki Ohyagi, Tetsuya Nagata, Kensuke Ihara, et al.
Journal of Nanobiotechnology|February 1, 2023
Peripheral administration of nanomicelle-encapsulated anti-Aβ oligomer fragment antibody reduces various toxic Aβ species in the brainAkiko Amano, Nobuo Sanjo, Wataru Araki, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 19, 2018
Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model NeonatesKenji Rowel Q Lim, Yusuke Echigoya, Tetsuya Nagata, et al.
Pageof 8